drugset / Trial / NCT02480764

Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

NCT02480764

Phase 3 Completed 612 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the antihypertensive effect of azilsartan medoxomil compared with valsartan in Chinese participants with essential hypertension.

Timeline

Start
2015-08-27
Primary completion
2017-09-22
Completion
2017-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan medoxomil Other / unclassified 40 mg Oral
Subject Azilsartan medoxomil Other / unclassified 80 mg Oral
Subject Valsartan Small molecule 160 mg Oral